Announcements Trials
Browse Landscape

Phase

Phase 1/2 1

Status

Active not recruiting 8Recruiting 7Not yet recruiting 5Completed 5Withdrawn 4Suspended 1

Sponsor Class

NIH 1

Study Type

Interventional 1

Sponsor

Cancer Type

Thoracic 1

Conditions

Neoplasm, Residual 1Carcinoma, Non-Small-Cell Lung 1Carcinoma 1

Interventions

Specimen Handling 35Magnetic Resonance Spectroscopy 23Biopsy 22Cyclophosphamide 11venetoclax 7Nivolumab 6Azacitidine 6pembrolizumab 5Taxes 5Etoposide 5Cisplatin 5Bevacizumab 5fludarabine phosphate 4fludarabine 4X-Rays 4Vincristine 4Surgical Procedures, Operative 4Radiosurgery 4Radiation 4Gemcitabine 4Doxorubicin 4Cetuximab 4130-nm albumin-bound paclitaxel 4durvalumab 3decitabine and cedazuridine drug combination 3cemiplimab 3Tacrolimus 3Surveys and Questionnaires 3Radiotherapy, Intensity-Modulated 3Prednisone 3

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Suspended × ALT-803 × 1 year × Clear all
NCT05642195 2026-06-05

Evaluation of a Cancer Lysate Vaccine and Montanide (Registered Trademark) ISA-51 VG With or Without the IL-15 Super-Agonist N-803 as Adjuvant Therapy for PD-L1 Negative Non-Small Cell Lung Cancer

National Institutes of Health Clinical Center (CC)

Phase 1/2 Suspended
30 enrolled
Thoracic

Carcinoma, Carcinoma, Non-Small-Cell Lung, Neoplasm, Residual

Data powered by HemOnc (CC BY 4.0) Colophon âš¡